Fisher Asset Management LLC decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 87.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,467 shares of the company’s stock after selling 118,637 shares during the quarter. Fisher Asset Management LLC’s holdings in Neurocrine Biosciences were worth $2,336,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth about $2,310,886,000. Renaissance Technologies LLC grew its holdings in shares of Neurocrine Biosciences by 8.0% during the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock worth $318,665,000 after buying an additional 180,100 shares in the last quarter. First Trust Advisors LP raised its position in shares of Neurocrine Biosciences by 97.0% in the first quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock valued at $126,367,000 after buying an additional 472,408 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Neurocrine Biosciences in the second quarter valued at approximately $117,827,000. Finally, Ieq Capital LLC acquired a new position in shares of Neurocrine Biosciences in the second quarter valued at approximately $107,914,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Neurocrine Biosciences
In other Neurocrine Biosciences news, insider David Boyer sold 826 shares of Neurocrine Biosciences stock in a transaction on Monday, September 14th. The shares were sold at an average price of $157.45, for a total value of $130,053.70. Following the transaction, the insider owned 8,722 shares in the company, valued at $1,373,278.90. This trade represents a 8.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George J. Morrow sold 7,500 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $145.79, for a total transaction of $1,093,425.00. Following the sale, the director directly owned 10,386 shares of the company’s stock, valued at $1,514,174.94. This represents a 41.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,137 shares of company stock worth $2,829,332 in the last quarter. 4.60% of the stock is owned by insiders.
Neurocrine Biosciences Price Performance
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, topping the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 23.39%. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the prior year, the business posted $2.04 earnings per share. Neurocrine Biosciences’s revenue for the quarter was up 41.3% compared to the same quarter last year. Analysts expect that Neurocrine Biosciences, Inc. will post 8.41 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on NBIX. Weiss Ratings raised shares of Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 14th. Piper Sandler lifted their target price on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. Stifel Nicolaus boosted their price target on Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a report on Friday, July 31st. Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 4th. Finally, BMO Capital Markets decreased their price objective on Neurocrine Biosciences from $164.00 to $150.00 and set a “market perform” rating on the stock in a report on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average price target of $202.59.
Get Our Latest Analysis on NBIX
Neurocrine Biosciences Company Profile
Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.
See Also
- Five stocks we like better than Neurocrine Biosciences
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
